Expandable percutaneous sheath

Information

  • Patent Grant
  • 10349976
  • Patent Number
    10,349,976
  • Date Filed
    Monday, January 25, 2016
    8 years ago
  • Date Issued
    Tuesday, July 16, 2019
    4 years ago
Abstract
Disclosed is an expandable percutaneous sheath, for introduction into the body while in a first, low cross-sectional area configuration, and subsequent expansion to a second, enlarged cross-sectional configuration. The sheath is maintained in the first, low cross-sectional configuration by a tubular restraint. In one application, the sheath is utilized to provide access for a diagnostic or therapeutic procedure such as percutaneous nephrostomy or urinary bladder access.
Description
RELATED APPLICATIONS

This application claims priority to U.S. patent application Ser. No. 10/728,728 filed Dec. 5, 2003 entitled Expandable Percutaneous Sheath, which is hereby incorporated herein by reference in its entirety.


BACKGROUND OF THE INVENTION

Field of the Invention


The present invention relates to medical devices and, more particularly, to methods and devices for forming a percutaneous channel. In one application, the present invention relates to methods and devices for providing percutaneous access to a soft tissue or organ.


Description of the Related Art


A wide variety of diagnostic or therapeutic procedures involve the introduction of a device through a natural or artificially created access pathway. A general objective of access systems, which have been developed for this purpose, is to minimize the cross-sectional area of the puncture, while maximizing the available space for the diagnostic or therapeutic instrument. These procedures include, among others, a wide variety of laprascopic diagnostic and therapeutic interventional procedures.


Percutaneous nephrostomy is an example of one type of therapeutic interventional procedure that requires an artificially created pathway. Percutaneous nephrostomy is a minimally invasive procedure that can be used to provide percutaneous access to the upper urinary tract. At first, percutaneous nephrostomy was used only for urinary diversion but now it may be used for more complex procedures such as stone extraction, integrate endopyelotomy, and resection of transitional cell carcinoma of the upper urinary tract.


In many percutaneous nephrostomy systems, a stiff guidewire is first placed into the renal collection system through the renal parenchyma and the ureter using fluoroscopic control. A second “safety wire” may be placed with a dual lumen catheter for maintaining the tract should the first wire become dislodged or kinked.


Once guidewire control is established, a dilator sheath is used to create the tract and establish a rigid working lumen. An early technique involved advancing a flexible, 8 French, tapered catheter over the first guidewire to provide guidewire protection as well as a stable path for the placement of larger diameter dilators and sheaths. The larger diameter sheaths are sequentially advanced over the catheter and each other until an approximately 34 French tract is established. The inner sheaths or dilators may then be sequentially removed such that the outermost sheath defines a working lumen. In this system, tract formation is accomplished by the angular shearing force of each subsequent sheath placement, which cuts a path through the tissue. Because axial pressure is required to advance and place each sheath, care must be taken to avoid kinking the tapered catheter and/or advancing the sheaths to far and perforating the renal pelvis. This technique also requires a large number of steps.


A more recent technique utilizes a balloon that is advanced over the first guide wire. Once in place in the renal pelvis, the balloon is inflated with a dilute contrast media solution to enlarge the tract. Once the balloon is inflated to a suitable diameter, a rigid sheath is advanced over the balloon. Advancing the rigid sheath over the balloon typically requires applying axial force to the sheath and rotation. The balloon may then be deflated and removed from the rigid sheath so that the rigid sheath may define a working lumen. In general, this technique is considered less traumatic than the previously described technique. Nevertheless, placement of the rigid sheath still involves angular shearing forces and several steps.


Additional information regarding percutaneous nephrostomy can be found in McDougall, E. M., et al. (2002), Percutaneous Approaches to the Upper Urinary Tract, Campbell's Urology. 8th ed, vol. 4, pp. 3320-3357, Chapter 98. Philadelphia, Saunders.


A need therefore remains for improved access technology which allows a device to be percutaneously passed through a small diameter tissue tract, while accommodating the introduction of relatively large diameter instruments.


SUMMARY OF THE INVENTION

A percutaneous access sheath is provided according to an embodiment of the present invention. In one application, the percutaneous access sheath is used to provide access to the upper urinary tract or bladder.


In one embodiment, the percutaneous access sheath may be used in conjunction with a deployment catheter, which may be provided with a balloon at its distal end. The percutaneous access sheath has a proximal section and a variable diameter distal section. The deployment catheter may be disposed within the percutaneous access sheath such that the balloon is positioned within the distal section of the percutaneous access sheath.


In one embodiment, the distal section of the percutaneous access sheath is restrained in a first, small diameter by a releasable restraint such as a perforated, scored or thin wall continuos film insert jacket. The distal section of the percutaneous access sheath is creased by at least 2 to 4 or 2 to 6 folds and inserted into a distal section of the jacket. This gives the percutaneous access sheath a smaller cross-sectional profile, facilitating its insertion.


In one embodiment, the folded percutaneous access sheath is restrained within the jacket. Following insertion into a patient's anatomy, the jacket may be released by inflating the balloon on the deployment catheter. During the inflation process, the jacket separates along its longitudinal axis as the access sheath unfolds and/or expands. In one preferred embodiment, separation of the jacket during inflation, occurs along a perforated or scored line formed on the jacket. In one such embodiment, the score or perforation may be formed at or close to the distal end of the jacket such that the jacket separates at the distal end first. In another preferred embodiment, the jacket is formed from a continuous film and the separation is caused by stretching the film until it separates. After the balloon has expanded the access sheath to its full diameter and caused the jacket to separate, the jacket may be withdrawn from the patient's anatomy. In a modified embodiment, the jacket may remain coupled to the access sheath during use. The balloon may be deflated to allow the removal of the deployment catheter, leaving the percutaneous access sheath in place.


In one embodiment where the percutaneous access sheath is used to provide access to the upper urinary tract, the percutaneous access sheath may be used to provide access by tools adapted to perform biopsy, urinary diversion, stone extraction, antegrade endopyelotomy, and resection of transitional cell carcinoma and other diagnostic or therapeutic procedures of the upper urinary tract or bladder


Other applications of the percutaneous access sheath include a variety of diagnostic or therapeutic clinical situations which require access to the inside of the body, through either an artificially created or natural body lumen.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1 is a side elevational view of a percutaneous access sheath.



FIG. 1A is a front view of the percutaneous access sheath.



FIG. 2 is a side elevational view of a jacket.



FIG. 3 illustrates the percutaneous access sheath in a reduced cross-sectional configuration and inserted into the jacket.



FIG. 4 is a side elevational view of an access sheath expansion balloon catheter.



FIG. 5 is an enlarged view of the distal end of the expansion balloon catheter.



FIG. 6 is an enlarged view of the proximal end of the expansion balloon catheter.



FIG. 7 illustrates the percutaneous access sheath assembly, with the expansion balloon catheter inserted into the structure illustrated in FIG. 3.



FIG. 8 illustrates the percutaneous access sheath assembly of FIG. 7 in an expanded configuration and the jacket removed.



FIG. 9 illustrates the percutaneous access sheath assembly of FIG. 7 inserted into a renal calyx of a kidney, in a first, low profile configuration.



FIG. 10 illustrates the percutaneous access sheath assembly of FIG. 9 with the jacket removed.



FIG. 11 illustrates the percutaneous access sheath assembly of FIG. 10 with the jacket removed and the expansion catheter fully expanded in a second, functional configuration.



FIG. 12 illustrates the percutaneous access assembly of FIG. 11 with the expansion catheter removed.





DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT


FIG. 1 is an overview of an exemplary embodiment of a percutaneous access sheath 100. The sheath 100 generally comprises an elongate tubular body 102 with an axial lumen 108 (FIG. 1A), and is designed to provide percutaneous access to a diagnostic or treatment site in the body.


In the exemplary embodiment, the elongate tubular body 102 has a distal section 110 and a proximal section 103. The proximal section 103 has a slightly larger inner and outer diameter as compared to the distal section 110. As will be explained in more detail below, the proximal section 103 may be used to secure the access sheath 100 to a connector. With continued reference to FIG. 1, the distal end 104 of the distal section 110 may be provided with a beveled distal face 111, which preferably forms an angle of about 45 to about 75 degrees with respect a longitudinal axis of the tubular body 102. In this manner, the distal face 111 forms a leading edge 105a and a trailing edge 105b. As will be explained below, during insertion, the beveled face 111 advantageously provides the distal end 104 of the access sheath 100 with a smaller cross-sectional profile in a compressed configuration. This provides a smoother transition from the distal end 104 of the access sheath 100 to the deployment catheter (described below). In addition, in the expanded configuration, the leading edge 105a maintains positional purchase within the target tissue or organ while the trailing edge 105b provides the sheath 100 with an aperture to facilitate instrument maneuvering and visualization within the internal structure of the tissue or organ under examination or treatment. In a modified embodiment, the distal face 111 may be form an angle of about 90 degrees with respect to the longitudinal axis of the tubular body.


The length and diameter of the sheath 100 can be varied according to clinical need, as will be understood by those skilled in the art with reference to this disclosure. In one exemplary embodiment for percutaneous nephrostomy, the access sheath 100 has an overall length of about 17 to about 30 centimeters with the distal section 110 having a length of about 11 to about 24 centimeters. As will be explained in more detail below, a portion or all of the distal section 110 is expandable from a first, smaller cross-sectional profile to a second, larger cross-sectional profile. The first, smaller cross-sectional profile of the distal section 110 eases its insertion into a percutaneous treatment site. After insertion, the distal section 110 is expanded to a second, larger cross-sectional profile to provide a larger passageway for surgical instruments to reach the percutaneous treatment site. For percutaneous nephrostomy, the smaller cross-sectional profile may have a diameter of about 15 French to about 24 French and the larger cross-sectional profile may have a diameter of about 21 French to about 40 French. In the larger cross-sectional profile, the lumen 108 may have a diameter of about 18 French to about 38 French.


As mentioned above, in the illustrated embodiment, the percutaneous access sheath 100 comprises a tubing 102, which defines a lumen 108. The tubing 102 may be made of PTFE, nylon, PEBAX or polyethylene, polyurethane, silicone, or other suitable materials.


In this embodiment, the distal section 110 is creased in at least two and more preferably 2 to 6 sections, most preferably 2 to 4 sections, and collapsed from a larger to a smaller cross-sectional profile to ease its insertion. As discussed below, in one embodiment for percutaneous nephrostomy, the distal section 110 is placed into the renal collecting system through the renal parenchyma and ureters. Its length is thus determined by the anatomy and is generally in the range of about 11 cm to about 24 cm. In the illustrated embodiment, the proximal end 103 of the tubing 102 is flared and fitted onto the deployment catheter as will be explained below. The overall length of the tubing 102 depends on the distance between the insertion and treatment locations, and is generally in the range of 10-100 cm for various clinical indications. As mentioned above, for percutaneous nephrostomy, the length of the tubing is approximately 17-30 cm.



FIG. 2 is an overview of the jacket 200. It is preferably made of a thin, smooth and flexible material. The jacket 200 has a proximal section 207 and a distal, restraint section 210. The restraint section 210 has a smaller cross-sectional profile than the proximal section 207 of the jacket 200. The restraint section 210 is adapted to restrain a portion or all of the distal section 110 of the percutaneous access sheath 100 in a smaller cross-sectional profile. This is achieved by constraining the percutaneous access sheath 100 in the jacket 200 such that all or a portion of the distal section 110 of the percutaneous access sheath 100 lies within the restraint section 210 of the jacket 200.


In the illustrated embodiment, the jacket 200 may be made of heat shrink PTFE. The proximal end 202 of the jacket 200 terminates at a pull tab 204, which may be formed by any of a variety of structures such as a threaded connector with a luer lock at its proximal end. The jacket 200 may be provided with a slit 206 near its proximal end 202. The jacket 200 tapers at a first tapering point 208 into a restraint section 210, which tapers again into the distal tip 212. As discussed above, the restraint section 210 restrains the distal section 110 of the percutaneous access sheath 100 in its smaller cross-sectional profile. Thus the length of the restraint section 210 is approximately the same as or slightly longer or shorter than the distal section 110, and generally falls in the range of about 1 l-25 cm.


The outside diameter of the restraint section 210 is preferably configured to ease its insertion into a percutaneous treatment site. Depending upon the clinical application, the outside diameter may be in the range of about 3 French to about 40 French. For percutaneous nephrostomy, the outside diameter may be in the range of about 5 French to about 35 French. The restraint section 210 is configured to separate and/or tear preferably along its longitudinal axis to release the access sheath 100 as it is radially expanded. In the illustrated embodiment, the jacket 200 is perforated, scored or otherwise provided with a tear line 215 from the first tapering point 208 to its distal tip 212. In another embodiment, the jacket 200 may be constructed of a material that will disrupt or separate during expansion from the first tapering point 208 to its distal tip 212. In another embodiment, the jacket 200 may be perforated, scored or otherwise provided with a tear line for only a portion of the restraint section 210. For example, in one embodiment, the restraint section 210 may be provided with a tear line at a region close to or at the distal end of the jacket 200. This may cause the jacket 200 to disrupt or separate during expansion from its distal end first


The distance between the slit 206 and the distal tip 212 is generally approximately equal to or longer than the length of the folded, compressed portion of the tubing 102 such that the folded compressed portion of the tubing 102 terminates within the restraint section 210. In one embodiment, this arrangement permits complete disruption of the jacket 200 when the access sheath 100 is fully expanded. In one embodiment, the distance between the slit 206 and the distal tip 212 is generally in the range of 6-90 cm for most clinical applications and about 11-24 cm for percutaneous nephrostomy. In the illustrated embodiment, which is configured for percutaneous nephrostomy, this distance is approximately 1 lcm, and the overall length of the jacket 200 is approximately 19 cm.



FIG. 3 illustrates the percutaneous access sheath 100 inserted into the jacket 200 via the slit 206 provided near its proximal end 202. The diameter of the restraint section 210 of the jacket 200 is smaller than the diameter of the distal section 110 of the tubing 102. In the illustrated embodiment, the distal section 110 is creased and folded inwards to decrease its effective diameter, and inserted into the restraint section 210. As discussed above, the restraint section 210 restrains the distal section 110 of the percutaneous access sheath 100 in its smaller cross-sectional profile. The restraint section 210 may be approximately the same length as or shorter than the distal section 110. In the illustrated embodiment, the restraint section 210 is approximately 11-24 cm.


As will be explained in more detail below, in some embodiments, the jacket 200 is removed from the access sheath 100 and the surgical site after the sheath 100 is expanded. In other embodiments, the jacket 200 is attached to the sheath 100 and remains attached to the sheath 100 after it is expanded and during the surgical procedure. In such latter embodiments, the jacket 200 may be securely attached to the access sheath by, for example, at least one adhesive or heat bond, preferably extending axially along a section of the access sheath 100 generally opposite the folds or creases.


In certain embodiments a jacket 200 may not be necessary if the distal section 110 of the percutaneous access sheath 100 is made of a stretchable material that may be stretched from a first, smaller cross-sectional profile to a second, larger cross-sectional profile. In these embodiments the outer surface of the distal section 110 is preferably made of a smooth material to facilitate the insertion of the percutaneous access sheath 100 into a treatment site. In still other embodiments, the jacket 200 may be a stretchable material that may be stretched with or without elastic deformation from a first, smaller cross-sectional profile to a second, larger cross-sectional profile as the sheath is expanded.



FIG. 4 is an overview of the deployment catheter 300. It is provided with an expansion element such as balloon 310. As will be explained in more detail below, the deployment catheter 300 is inserted into the lumen 108 of the percutaneous access sheath 100 such that the balloon 310 is arranged within the distal section 110. The balloon 310 may then be inflated to expand the distal section 110 from its first, smaller cross-sectional profile to its second, larger cross-sectional profile following the insertion of the percutaneous access sheath 100 into a treatment site.


With particular reference to FIG. 4, an inner tube 302 extends the entire length of the deployment catheter 300. A guide wire lumen 304 is defined by the interior of the inner tube 302. The deployment catheter 300 can travel along a guide wire extending through the guide wire lumen 304. The inner tube 302 carries coaxially on its exterior an outer tube 306. The outer tube 306 terminates proximally into the distal end of a y-connector 308, and distally into a balloon 310. The balloon 310 may be made of PET. The y-connector 308 may be provided with an optional support tube (not shown) extending from its distal end and over a proximal section of the outer tube 306, to increase the rigidity of the deployment catheter 300 during insertion. This support tube may be made of any of a variety of materials, such as, a stainless steel hypotube.



FIG. 5 is an enlarged view of the distal end 314 of the exemplary embodiment of the deployment catheter 300. Both the inner tube 302 and the guide wire lumen 304 extend through the distal end 314 of the balloon 310. The inner tube 302 may carry coaxially on its exterior a pair of marker rings 316a, 316b near the distal end 314 of the balloon 310. With reference to FIG. 8, the pair of markers 316a, 316b are spaced apart such that when the deployment catheter 300 is inserted into the lumen 108 and expanded they correspond to the distal edge 105 a and proximal edge 105b of the beveled distal face 111 (see FIG. 1). In a modified arrangement, the markers 316a, 316b may be carried by the distal end 314 of the balloon 310. The markers 316a,b ma be made of gold, tantalum, platinum or another radio-opaque material. Additional markers may be provided on the deployment catheter to aid in visualizing its location. In another embodiment, the markers 316a, 316b may be replaced with a single axially elongated marker having a leading and trailing edge that corresponds to the distal edge 105a and proximal edge 105b of the beveled distal face 111.


With reference back to FIG. 4, a balloon inflation lumen 318, defined in the space between the inner tube 302 and the outer tube 306, communicates with the interior of the balloon 310. As discussed above, the balloon 310 may be inflated to expand the distal section 110 of the percutaneous access sheath 100 from its first, smaller cross-sectional profile to its second, larger cross-sectional profile. Thus the length of the balloon 310 is approximately equal to or slightly longer than the length of the distal section 110. In the illustrated embodiment, which is configured for percutaneous nephrostomy the length of the balloon 310 is approximately 12.5 cm. For other clinical applications, the length of the balloon 310 may be in the range of about 8-90 cm.



FIG. 6 is an enlarged view of the proximal end of the illustrated embodiment of the deployment catheter 300. Both the inner tube 302 and the guide wire lumen 304 extend through the distal end of the y-connector 308. The balloon inflation lumen 318, defined in the space between the inner tube 302 and the outer tube 306, opens into a port 320 in the y-connector 308. The illustrated embodiment uses a pair of stoppers 322a, 322b to align the inner tube 302 within the y-connector 308 and prevent the balloon inflation lumen 318 from communicating with the space 324 in the main branch of the y-connector 308. Thus only the port 320 communicates via the balloon inflation lumen 318 with the interior of the balloon. A pump may be connected to the port 320 to inflate or deflate the balloon. To enable visualization of the state of the balloon, it may be inflated with contrast media.



FIG. 7 illustrates the percutaneous access sheath assembly 150 in a collapsed or smaller profile configuration. The percutaneous access sheath assembly 150 comprises the percutaneous access sheath 100, the jacket 200 and the deployment catheter 300. It is assembled by inserting the deployment catheter 300 into the percutaneous access sheath 100 and inserting the percutaneous access sheath 100 into the jacket 200 such as via the slit 206 or other proximal opening provided near its proximal end 202. The balloon 310, which is not shown in FIG. 7, of the deployment catheter 300 is deflated, folded and inserted into the distal section 110 of the access sheath 100. The distal section 110, as discussed above, is creased and folded inwards to decrease its effective diameter, and inserted into the restraint section 210 of the jacket 200. As discussed, the balloon 310 is approximately the same length as or just longer than the distal section 110 and the restraint section 210.



FIG. 8 illustrates the percutaneous access sheath assembly 150 in an expanded or larger profile configuration. In the expanded configuration, the jacket 200 has been removed and the balloon 310 has been inflated to expand the distal section 110 of the access sheath 100.


One exemplary embodiment of use will now be described with reference to FIGS. 9-12. As shown in FIG. 9, a guidewire 400 may be placed into the renal collection system. In one embodiment, the guidewire 400 is inserted through the renal parenchyma and the ureter using fluoroscopic control. The guidewire 400 may be 0.038″ stiff guidewire that is inserted through a small (e.g., 1.7 to two centimeter) incision made at the guidewire skin entry cite. A second “safety wire” 402 may be placed with a dual lumen catheter (not shown) for maintaining the tract should the first wire become dislodged or kinked.


The guide wire 400 may be inserted into the guide wire lumen 304 (see FIG. 4) of the deployment catheter 300 of the percutaneous access sheath assembly 150. The entire assembly 150 may travel over the guide wire 400 until its distal tapered portion is positioned just within the renal pelvis. As mentioned above, the distal tip 314 is preferably provided with a pair of radiopaque tip markers 316a, 316b to aid placement. The jacket 200, which is on the exterior of the percutaneous access sheath assembly 150, facilitates the insertion because of its smooth, low profile exterior.


Following the insertion of the percutaneous access sheath assembly 150, the access sheath 100 may be expanded and released from the jacket 200. This may be accomplished by inflating, at least partially, the balloon 310 (not visible in FIG. 10) and radially expanding the access sheath 100 until the jacket 200 separates, preferably along the longitudinal axis of the jacket 200. As discussed above, the balloon 310 is arranged within the distal section 110 of the percutaneous access sheath 100, which is itself arranged within the restraint section 210 of the jacket 200. Thus, inflating the balloon 310 causes the distal section 110 of the percutaneous access sheath 100 to expand, tearing or separating the restraint section 210 of the jacket 200 preferably along its longitudinal axis.


After the sheath 100 is released from the jacket 200, the balloon 310 may be fully inflated to expand the distal section 110 of the percutaneous access sheath to its full cross-sectional profile. See FIG. 11. In one embodiment, the balloon 310 is inflated by providing a pump (e.g., a high pressure balloon inflation syringe) with about 20-25 cc of a diluted contrast media (e.g., a 50% solution of Renografin® and sterile saline). After removing the air from the pump and associated tubing, the pump may be attached to the inflation/deflation port of the central balloon shaft. Preferably, under fluoroscopic control, the dilute contrast media is slowly injected until a maximum pressure of about 12 bar is achieved. Inflation pressure is preferably maintained for a minimum of about 60 seconds to reduce or eliminate any “waist” (i.e., partially unexpanded sections) that may remain along the length of the expanded sheath 100.


In some embodiments, after the sheath 100 has been released from the jacket 200, the jacket 200 may be removed from the access sheath 100 and the surgical cite. In other embodiments, the jacket 200 may remain attached to the access sheath 100 during use. As explained above, in such embodiments, the jacket 200 may be securely attached to the access sheath by, for example, an adhesive or heat bond.


After the balloon 310 is inflated, it may be deflated to ease the removal of the deployment catheter 300. As discussed above, the inflation and deflation of the balloon 310 may be done via a pump connected to the port 320 of the deployment catheter 300, and preferably with a dilute contrast media being pumped, to better convey the state of the balloon.


Thus, the percutaneous access sheath 100 extends into the renal pelvis and provides a working lumen. See FIG. 12. The establishment of this working lumen may provide access for several procedures such as biopsy, stone extraction, antegrade endopyelotomy, and resection of transitional cell carcinoma of the upper urinary tract. As explained above, in the embodiments with a beveled edge 111, the leading edge 105a maintains positional purchase within the target tissue or organ while the trailing edge 105b provides the sheath 100 with an aperture to facilitate instrument maneuvering and visualization within the internal structure of the tissue or organ under examination or repair.


It will be apparent from the disclosure herein that the percutaneous access sheath 100, the percutaneous access sheath assembly 150, and/or the methods described herein may also find utility in a wide variety of diagnostic or therapeutic procedures that require an artificially created access tract. For example, the embodiments described herein may be used in many urological applications (e.g., the removal of ureteral strictures and stones, the delivery of drugs, RF devices and radiation for cancer treatment, etc.). In such applications, the percutaneous access sheath 100 may have a length of about 30-300 cm with an unexpanded diameter of about 7-20 French and an expanded diameter of about 14-60 French. The sheath 100 may also be used in many gastrointestinal applications, which require the introduction of a surgical retractor (e.g., to the removal gallstones and appendix procedures). In such applications, the percutaneous access sheath 100 may have a length of about 10-50 cm with an unexpanded diameter of about 3-15 French and an expanded diameter of about 15-60 French. The percutaneous access sheath 100 may also be used as an access catheter for many gastrointestinal applications (e.g., colon therapies, esophageal treatment and the treatment of bowel obstructions). In such applications, the percutaneous access sheath 100 may have a length of about 30-300 cm with an unexpanded diameter of about 7-40 French and an expanded diameter of about 14-120 French.


The sheath may also be used in many cardiovascular applications (e.g., to provide access for minimally invasive heart bypass, valve replacement or the delivery of drugs or angiogenesis agents). In such applications, the percutaneous access sheath 100 may have a length of about 30-300 cm with an unexpanded diameter of about 3-12 French and an expanded diameter of about 5-30 French. For vascular applications (e.g., minimally invasive access to the aorta or contralateral leg arteries for the treatment of, for example, an abdominal aortic aneurysm), the percutaneous access sheath 100 may have a length of about 30-300 cm with an unexpanded diameter of about 5-30 French and an expanded diameter of about 15-75 French. For gynecological applications (e.g., endometrial therapies, delivery of drugs, delivery of cancer agents, sterilization procedures, etc.), the percutaneous access sheath 100 may have a length of about 10-100 cm with an unexpanded diameter of about 3-20 French and an expanded diameter of about 6-60 French.


Although the present invention has been described in terms of certain preferred embodiments, other embodiments of the invention including variations in dimensions, configuration and materials will be apparent to those of skill in the art in view of the disclosure herein. In addition, all features discussed in connection with any one embodiment herein can be readily adapted for use in other embodiments herein. The use of different terms or reference numerals for similar features in different embodiments does not imply differences other than those which may be expressly set forth. Accordingly, the present invention is intended to be described solely by reference to the appended claims, and not limited to the preferred embodiments disclosed herein.

Claims
  • 1. A percutaneous access sheath assembly for providing minimally invasive access for percutaneous nephrostomy or bladder access comprising: a balloon catheter having a balloon positioned on its distal end and which carries at least a first marker and a second marker;a circumferentially continuous elongate tubular structure having an unfoldable and expandable distal region including a distal end that forms a distal face which is beveled with respect to a longitudinal axis of the elongate tubular structure, a proximal region, and a tapered region between the distal region and the proximal region, the distal region is configured to unfold and expand from a first, folded, smaller cross-sectional profile to a second, greater cross-sectional profile radially around a longitudinal axis of the elongate tubular structure by the balloon that is positioned within an interior lumen of the distal region and removable so as to allow access by devices within a patient, wherein the balloon catheter is arranged such that the first marker is aligned with a front edge of the distal face in an expanded position and the second marker is aligned with a rear edge of the distal face in an expanded position, anda constraining releasable jacket sharing the same longitudinal axis as the elongate tubular structure and being carried by the percutaneous access sheath assembly to restrain at least a portion of said elongate tubular structure in said first, smaller cross-sectional profile; the constraining releasable jacket being releasable by tearing the constraining releasable jacket along a perforation.
  • 2. The percutaneous access sheath assembly of claim 1, wherein the balloon is capable of being expanded in a radial direction to radially expand said portion of said elongate tubular structure.
  • 3. The percutaneous access sheath assembly of claim 1, wherein when said elongate tubular structure is in said first, smaller cross-sectional profile it has an outer diameter of about 10 French to about 30 French.
  • 4. The percutaneous access sheath assembly of claim 3, wherein when said elongate tubular structure is in said second, greater cross-sectional profile it has an outer diameter of about 15 to about 40 French.
  • 5. The percutaneous access sheath assembly of claim 1, wherein when said elongate tubular structure is in said second, greater cross-sectional profile it has an inner diameter of about 12 to about 37 French.
  • 6. The percutaneous access sheath assembly of claim 1, wherein the distal face forms an angle of about 45 to about 75 degrees with respect to the longitudinal axis of the elongate tubular structure.
  • 7. The percutaneous access sheath assembly of claim 1, wherein the balloon catheter is positioned within the elongate tubular structure, the balloon catheter carrying said balloon to expand said portion of said elongate tubular structure from said first, smaller cross-sectional profile to said second, greater cross-sectional profile.
  • 8. The percutaneous access sheath assembly of claim 1, wherein the constraining releasable jacket is attached to the elongate tubular structure.
  • 9. The percutaneous access sheath assembly of claim 8, wherein the constraining releasable jacket comprises a perforation.
  • 10. The percutaneous access sheath assembly of claim 8, wherein the constraining releasable jacket comprises a score line.
  • 11. The percutaneous access sheath assembly of claim 8, wherein the constraining releasable jacket is formed of a material that will separate along a longitudinal axis as the elongate tubular structure is expanded in a radial direction.
  • 12. The percutaneous access sheath assembly of claim 1, wherein the constraining releasable jacket comprises a perforation.
  • 13. The percutaneous access sheath assembly of claim 1, wherein the constraining releasable jacket comprises a score line.
  • 14. The percutaneous access sheath assembly of claim 1, wherein the constraining releasable jacket is formed of a material that will separate along a longitudinal axis as the elongate tubular structure is expanded in a radial direction.
  • 15. The percutaneous access sheath assembly of claim 1, wherein the constraining releasable jacket is not attached to the elongate tubular structure.
  • 16. The percutaneous access sheath assembly of claim 1, wherein when said portion of said elongate tubular structure is in said first smaller cross-sectional profile it is folded into at least 2 sections.
  • 17. The percutaneous access sheath assembly of claim 1, wherein when said portion of said elongate tubular structure is in said first smaller cross-sectional profile it is folded into 2 to 6 sections.
  • 18. The percutaneous access sheath assembly of claim 1, wherein said portion of said elongate tubular structure is capable of being expanded in response to a radial force.
  • 19. The percutaneous access sheath assembly of claim 1, wherein the entire elongate tubular structure is restrained by the constraining releasable jacket in said first, smaller cross-sectional profile.
US Referenced Citations (214)
Number Name Date Kind
319296 Molesworth Jun 1885 A
668879 Miller Feb 1901 A
1213001 Philips Jan 1917 A
1248492 Hill Dec 1917 A
2042900 James Jun 1936 A
2548602 Greenburg Apr 1951 A
3509883 Dibelius May 1970 A
3545443 Ansari Dec 1970 A
3742958 Rundles Jul 1973 A
3789852 Kim et al. Feb 1974 A
3902492 Greenhalgh Sep 1975 A
4018230 Ochiai et al. Apr 1977 A
4141364 Schultze Feb 1979 A
4338942 Fogarty Jul 1982 A
4401433 Luther Aug 1983 A
4411655 Schreck Oct 1983 A
4451256 Weikl et al. May 1984 A
4479497 Fogarty et al. Oct 1984 A
4581025 Timmermans Apr 1986 A
4589868 Dretler May 1986 A
4601713 Fuqua Jul 1986 A
4610668 Silvestrini et al. Sep 1986 A
4636346 Gold et al. Jan 1987 A
4637396 Cook Jan 1987 A
4650466 Luther Mar 1987 A
4710181 Fuqua Dec 1987 A
4716901 Jackson et al. Jan 1988 A
4738666 Fuqua Apr 1988 A
4739762 Palmaz Apr 1988 A
4748666 Fuqua May 1988 A
4772266 Groshong Sep 1988 A
4790817 Luther Dec 1988 A
4798193 Giesy et al. Jan 1989 A
4846791 Hattler et al. Jul 1989 A
4865593 Ogawa et al. Sep 1989 A
4869717 Adair Sep 1989 A
4884573 Wijay et al. Dec 1989 A
4888000 McQuilkin et al. Dec 1989 A
4896669 Bhate et al. Jan 1990 A
4898581 Jang et al. Feb 1990 A
4899729 Gill et al. Feb 1990 A
4921479 Grayzel May 1990 A
4954126 Wallsten Sep 1990 A
4955895 Sugiyama et al. Sep 1990 A
4972827 Kishi et al. Nov 1990 A
4984564 Yuen Jan 1991 A
4986830 Owens et al. Jan 1991 A
5001488 Ginsburg et al. Apr 1991 A
5011488 Ginsburg et al. Apr 1991 A
5035686 Crittenden et al. Jul 1991 A
5045056 Behl Sep 1991 A
5057092 Webster, Jr. Oct 1991 A
5066285 Lundquist et al. Nov 1991 A
5073166 Parks et al. Dec 1991 A
5078736 Behl Jan 1992 A
5092839 Kipperman Mar 1992 A
5098393 Amplatz et al. Mar 1992 A
5100388 Behl et al. Mar 1992 A
5108413 Moyers Apr 1992 A
5108416 Ryan et al. Apr 1992 A
5112304 Barlow et al. May 1992 A
5112308 Olsen et al. May 1992 A
5116318 Hillstead May 1992 A
5122122 Allgood Jun 1992 A
5139511 Gill et al. Aug 1992 A
5147316 Castillenti Sep 1992 A
5158545 Trudell Oct 1992 A
5163903 Crittenden et al. Nov 1992 A
5176659 Mancini Jan 1993 A
5183464 Dubrul Feb 1993 A
5188602 Nichols Feb 1993 A
5201756 Horzewski et al. Apr 1993 A
5222938 Behl Jun 1993 A
5222971 Willard et al. Jun 1993 A
5234425 Fogarty et al. Aug 1993 A
5250025 Sosnowski et al. Oct 1993 A
5250033 Evans et al. Oct 1993 A
5256150 Quiachone et al. Oct 1993 A
5275611 Behl Jan 1994 A
5295994 Bonutti Mar 1994 A
5312360 Behl May 1994 A
5312417 Wilk May 1994 A
5316360 Feikma May 1994 A
5318588 Horzewski et al. Jun 1994 A
5320611 Bonutti et al. Jun 1994 A
5324261 Amundson et al. Jun 1994 A
5346503 Chow et al. Sep 1994 A
5380304 Parker Jan 1995 A
5392677 Masterson et al. Feb 1995 A
5395341 Siater Mar 1995 A
5395349 Quiachon et al. Mar 1995 A
5407430 Peters Apr 1995 A
5409469 Schaerf Apr 1995 A
5431676 Dubrul et al. Jul 1995 A
5433708 Nichols et al. Jul 1995 A
5447503 Miller Sep 1995 A
5454790 Dubrul Oct 1995 A
5460170 Hammerslag Oct 1995 A
5507767 Maeda et al. Apr 1996 A
5514091 Yoon May 1996 A
5514236 Avellanet et al. May 1996 A
5527336 Rosenbluth Jun 1996 A
5540658 Evans et al. Jul 1996 A
5542928 Evans et al. Aug 1996 A
5549635 Solar Aug 1996 A
5571089 Crocker Nov 1996 A
5573509 Thornton Nov 1996 A
5573517 Bonutti et al. Nov 1996 A
5573520 Schwartz Nov 1996 A
5657963 Hincliffe et al. Aug 1997 A
5662614 Edoga Sep 1997 A
5674240 Bonutti et al. Oct 1997 A
5674857 Anderson et al. Oct 1997 A
5700253 Parker Dec 1997 A
5702373 Samson Dec 1997 A
5709713 Evans et al. Jan 1998 A
5713867 Morris Feb 1998 A
5738667 Solar Apr 1998 A
5766203 Imran et al. Jun 1998 A
5776141 Klein et al. Jul 1998 A
5810776 Bacich et al. Sep 1998 A
5817100 Igaki Oct 1998 A
5846251 Hart Dec 1998 A
5868779 Ruiz Feb 1999 A
5869719 Tsukernik Feb 1999 A
5885217 Gisselberg et al. Mar 1999 A
5888196 Bonutti Mar 1999 A
5897557 Chin et al. Apr 1999 A
5902282 Balbierz May 1999 A
5908435 Samuels Jun 1999 A
5916145 Chu et al. Jul 1999 A
5922019 Hankh et al. Jul 1999 A
5961499 Bonutti et al. Oct 1999 A
5964730 Williams et al. Oct 1999 A
5971938 Hart et al. Oct 1999 A
5997508 Lunn et al. Dec 1999 A
6030364 Durgin et al. Feb 2000 A
6056718 Funderburk et al. May 2000 A
6063056 Engelberg May 2000 A
6080174 Dubrul et al. Jun 2000 A
6090072 Kratoska et al. Jul 2000 A
6120480 Zhang et al. Sep 2000 A
6123689 To et al. Sep 2000 A
6168579 Tsugita Jan 2001 B1
6183443 Kratoska et al. Feb 2001 B1
6187000 Davison et al. Feb 2001 B1
6197016 Fourkas et al. Mar 2001 B1
6228052 Pohndorf May 2001 B1
6248116 Chevillon et al. Jun 2001 B1
6280452 Mears Aug 2001 B1
6293909 Chu et al. Sep 2001 B1
6312443 Stone Nov 2001 B1
6358238 Sherry Mar 2002 B1
6443979 Stalker et al. Sep 2002 B1
6447540 Fontaine et al. Sep 2002 B1
6471684 Dulak et al. Oct 2002 B2
6494860 Rocamora et al. Dec 2002 B2
6494893 Dubrul et al. Dec 2002 B2
6517551 Driskill Feb 2003 B1
6524268 Hayner et al. Feb 2003 B2
6524320 DiPoto Feb 2003 B2
6530902 Jonkman Mar 2003 B1
6582395 Burkett et al. Jun 2003 B1
6613038 Bonnutti et al. Sep 2003 B2
6613062 Leckrone et al. Sep 2003 B1
6616678 Nishtala et al. Sep 2003 B2
6638268 Niazi Oct 2003 B2
6679902 Boyle et al. Jan 2004 B1
6692462 Mackenzie et al. Feb 2004 B2
6706017 Dulguerov Mar 2004 B1
6808520 Fourkas Oct 2004 B1
6827683 Otawara Dec 2004 B2
6951555 Suresh et al. Oct 2005 B1
7033369 Davison et al. Apr 2006 B2
7056319 Aliperti et al. Jun 2006 B2
7135015 Dulak et al. Nov 2006 B2
7309334 Von Hoffman Dec 2007 B2
7316677 Dulak et al. Jan 2008 B1
7329268 Van Nguyen et al. Feb 2008 B2
7457661 Doty Nov 2008 B2
20010012950 Nishtala et al. Aug 2001 A1
20010037126 Stack et al. Nov 2001 A1
20020009535 Michal et al. Jan 2002 A1
20020010440 Segesser Jan 2002 A1
20020010476 Mulholland et al. Jan 2002 A1
20020077653 Hudson et al. Jun 2002 A1
20020099431 Armstrong et al. Jul 2002 A1
20020161377 Rabkin Oct 2002 A1
20030050600 Ressemann et al. Mar 2003 A1
20030065353 Horzewski et al. Apr 2003 A1
20030135156 Bencini et al. Jul 2003 A1
20030195551 Davison et al. Oct 2003 A1
20030212384 Hayeden Nov 2003 A1
20030216770 Persidsky et al. Nov 2003 A1
20030233115 Eversull Dec 2003 A1
20040006344 Nguyen et al. Jan 2004 A1
20040073286 Armstrong et al. Apr 2004 A1
20040087968 Core May 2004 A1
20040181273 Brasington et al. Sep 2004 A1
20040220549 Dittman et al. Nov 2004 A1
20040236346 Parker Nov 2004 A1
20050043780 Gifford et al. Feb 2005 A1
20050085842 Eversull et al. Apr 2005 A1
20050124937 Kick et al. Jun 2005 A1
20050125021 Nance et al. Jun 2005 A1
20050149105 Leeflang et al. Jul 2005 A1
20050222576 Kick et al. Oct 2005 A1
20060036276 Nguyen et al. Feb 2006 A1
20060052750 Lenker et al. Mar 2006 A1
20060142795 Nguyen et al. Jun 2006 A1
20060200188 Nance et al. Sep 2006 A1
20060200189 Nance et al. Sep 2006 A1
20060247602 Dulak et al. Nov 2006 A1
20070112335 Dulak et al. May 2007 A1
Foreign Referenced Citations (12)
Number Date Country
0177177 Apr 1986 EP
0249456 Dec 1987 EP
024945611 Dec 1987 EP
0385920 Sep 1990 EP
0206553 Jan 1991 EP
0421650 Apr 1991 EP
0546766 Jun 1993 EP
WO1992019312 Nov 1992 WO
WO1995030374 Nov 1995 WO
WO1999016499 Apr 1999 WO
WO1999017665 Apr 1999 WO
WO2003090834 Nov 2003 WO
Non-Patent Literature Citations (54)
Entry
United States Patent and Trademark Office, Notice of Allowance dated Sep. 16, 2015 in U.S. Appl. No. 10/728,728, 9 pages.
United States Patent and Trademark Office, Examiner's Answer dated Jun. 21, 2012 in U.S. Appl. No. 10/y28,728, 13 pages.
United States Patent and Trademark Office, Final Office Action dated Jul. 22, 2011 in U.S. Appl. No. 10/728,728, 13 pages.
European Patent Office, Communication in European Application No. 04813043.9 filed on Dec. 3, 2004.
United States Patent and Trademark Office, Office Action dated Oct. 29, 2010 in U.S. Appl. No. 10/728,728, 14 pages.
United States Patent and Trademark Office, Final Office Action dated Mar. 22, 2010 in U.S. Appl. No. 10/728,728, 17 pages.
United States Patent and Trademark Office, Office Action dated Mar. 19, 2010 in U.S. Appl. No. 11/415,764.
United States Patent and Trademark Office, Response dated Oct. 16, 2009 to Non-final Rejection in U.S. Appl. No. 11/884,017.
United States Patent and Trademark Office, Response dated Sep. 15, 2009 to Office Action in U.S. Appl. No. 11/223,897.
United States Patent and Trademark Office, Office Action dated Jul. 23, 2009 in U.S. Appl. No. 10/728,728, 15 pages.
United States Patent and Trademark Office, Office Action dated Jul. 22, 2009 in U.S. Appl. No. 11/415,659.
United States Patent and Trademark Office, Final Office Action dated Jun. 30, 2009 in U.S. Appl. No. 11/415,764.
European Patent Office, Communication dated May 25, 2009 in European Patent Application No. 04813043.9.
United States Patent and Trademark Office, Response dated May 12, 2009 to Final Office Action in U.S. Appl. No. 11/223,897.
United States Patent and Trademark Office, Response dated May 11, 2009 to Final Office Action in U.S. Appl. No. 11/415,659.
United States Patent and Trademark Office, Office Action dated Apr. 17, 2009 in U.S. Appl. No. 11/884,017.
United States Patent and Trademark Office, Final Office Action dated Apr. 17, 2009 in U.S. Appl. No. 11/223,897.
United States Patent and Trademark Office, Final Office Action dated Apr. 6, 2009 in U.S. Appl. No. 11/415,659.
United States Patent and Trademark Office, Response dated Mar. 2, 2009 in U.S. Appl. No. 11/884,017.
United States Patent and Trademark Office, Final Office Action dated Feb. 19, 2009 in U.S. Appl. No. 10/728,728, 10 pages.
United States Patent and Trademark Office, Restriction Requirement dated Feb. 5, 2009 in U.S. Appl. No. 11/884,017.
United States Patent and Trademark Office, Response dated Feb. 3, 2009 to Office Action in U.S. Appl. No. 11/223,897.
European Patent Office, Response dated Jan. 15, 2009 to Jul. 14, 2008 Communication in European Application No. 05794899.4.
United States Patent and Trademark Office, Response dated Dec. 12, 2008 to Office Action in U.S. Appl. No. 11/415,764.
United States Patent and Trademark Office, Response dated Nov. 19, 2008 to Office Action in U.S. Appl. No. 11/415,659.
United States Patent and Trademark Office, Office Action dated Oct. 3, 2008 in U.S. Appl. No. 11/223,897.
European Patent Office, Response dated Aug. 11, 2008 to European Patent Office Communication dated Jan. 30, 2008 in European Patent Application No. 04813043.9.
European Patent Office, Communication dated Jul. 14, 2008 in European Patent Application No. 05794899.4
United States Patent and Trademark Office, Office Action dated Jun. 13, 2008 in U.S. Appl. No. 11/415,764.
United States Patent and Trademark Office, Office Action dated May 28, 2009 in U.S. Appl. No. 10/728,728, 20 pages.
United States Patent and Trademark Office, Office Action dated May 20, 2008 in U.S. Appl. No. 11/415,659.
United States Patent and Trademark Office, Response dated Feb. 20, 2008 to Final Office Action in U.S. Appl. No. 11/415,659.
United States Patent and Trademark Office, Response dated Feb. 20, 2008 to Office Action in U.S. Appl. No. 11/415,764.
European Patent Office, Communication dated Jan. 30, 2008 in European Patent Application No. 04813043.9.
United States Patent and Trademark Office, Advisory Action dated Nov. 16, 2007 in U.S. Appl. No. 11/415,659.
United States Patent and Trademark Office, Response dated Nov. 7, 2007 to Final Office Action in U.S. Appl. No. 11/415,659.
United States Patent and Trademark Office, Office Action dated Oct. 18, 2007 in U.S. Appl. No. 10/728,728, 9 pages.
European Patent Office, Examination Report dated Aug. 21, 2007 in European Patent Application No. 05794899.4.
United States Patent and Trademark Office, Final Office Action dated Aug. 20, 2007 in U.S. Appl. No. 11/415,659.
United States Patent and Trademark Office, Office Action dated Aug. 20, 2007 in U.S. Appl. No. 11/415,764.
United States Patent and Trademark Office, Response dated Jun. 11, 2007 to Office Action in U.S. Appl. No. 11/415,659.
United States Patent and Trademark Office, Response dated Jun. 8, 2007 to Office Action in U.S. Appl. No. 11/415,764.
United States Patent and Trademark Office, Notice of Allowance dated May 1, 2007 in U.S. Appl. No. 10/728,728, 11 pages.
WIPO, U.S. International Search Authority, International Search Report dated Apr. 3, 2007 in International Patent Application No. PCT/US2005/031958.
United States Patent and Trademark Office, Office Action dated Jan. 10, 2007 in U.S. Appl. No. 11/415,659.
United States Patent and Trademark Office, Office Action dated Jan. 8, 2007 in U.S. Appl. No. 11/415,764.
United States Patent and Trademark Office, Office Action dated Sep. 13, 2006 in U.S. Appl. No. 10/728,728, 14 pages.
United States Patent and Trademark Office, prosecution history in U.S. Patent Publication No. 2006/0200188 published Sep. 7, 2006.
United States Patent and Trademark Office, prosecution history in U.S. Patent Publication No. 2006/0200189 published Sep. 7, 2006.
WIPO, International Preliminary Examining Authority (U.S. Patent and Trademark Office), International Preliminary Report on Patentability dated Jun. 15, 2006 in International Patent Application No. PCT/US2004/040651.
WIPO, U.S. International Search Authority, International Search Report dated Jun. 7, 2006 in International Patent Application No. PCT/US2004/040651.
WIPO, U.S. International Search Authority, International Search Report dated Oct. 28, 2005 in International Patent Application No. PCT/US2004/040651.
United States Patent and Trademark Office, prosecution history in U.S. Patent Publication No. 2005/0125021 published Jun. 9, 2005.
United States Patent and Trademark Office, Office Action dated Jun. 30, 2009 in U.S. Appl. No. 11/223,897.
Related Publications (1)
Number Date Country
20160135840 A1 May 2016 US
Continuations (1)
Number Date Country
Parent 10728728 Dec 2003 US
Child 15006025 US